MSTN and congestive heart failure: Although myostatin may not be a feasible single biomarker of muscle wasting in CHF, our results suggest it might be viable in patients with HFmrEF and HFrEF, as well as a possible potent molecular grip point for future pharmacotherapeutic agents in this population of patients.